NF1 and neoplasm: The 2023 European Reference Network on Genetic Tumor Risk Syndromes (ERN GENTURIS) tumor surveillance guidelines for individuals with NF1 [15] provide a valuable, evidence-based decision-making resource for physicians treating patients with NF1.